Natalia Karczewska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natalia Karczewska has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Andrzej Pacak
Department of Gene Expression, Faculty of Biology Poznan, Adam Mickiewicz University, 61-614 Poznan, Poland
2 shared publications - Bartosz Sokół
Department of Neurosurgery, Poznan University of Medical Sciences, 60-355 Poznan, Poland
2 shared publications - Jolanta Florczak-Wyspiańska
Department of Neurology, Clinical Hospital of Poznan University of Medical Sciences, 60-355 Poznan, Poland
2 shared publications - Karolina Poplawska-Domaszewicz
Department of Neurology, Clinical Hospital of Poznan University of Medical Sciences, 60-355 Poznan, Poland
2 shared publications - Klaudia Pacewicz
Department of Bioenergetics, Faculty of Biology, Adam Mickiewicz University, 61-614 Poznan, Poland
2 shared publications - Małgorzata Wojtkowska
Institute of Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University, 61-614 Poznań, Poland
2 shared publications
Latest Publications
- Open Access
- 1 July 2024
- Published by Polskie Towarzystwo Biochemiczne (Polish Biochemical Society) in Postępy Biochemii
- Vol. 70 (2) , 230-245
Rola i wykorzystanie badań wysokoprzepustowych w poszukiwaniu związków chemicznych o działaniu terapeutycznym
With the development of medicine and the aging population, the demand for more effective therapies is escalating. A tool that facilitates the discovery and introduction of new therapeutic drugs is High-Throughput Screening (HTS). These tests, consisting of a wide set of various assays, allow testing hundreds of thousands of compounds in a short period of time. The aim is to accurately identify active compounds that could become potential therapeutic candidates in the pharmaceutical industry. HTS is the first step in the quest for potential drugs, therefore it is one of the crucial tests that determine whether a particular drug candidate will be discovered. In this review, different stages of high-throughput screening studies will be described, as well as methods utilized in these studies. The necessary steps in the optimization of these tests, selection of equipment, automation and key quality control parameters for reliably performed screening will also be presented.
- 1 July 2024
- Published by Polskie Towarzystwo Biochemiczne (Polish Biochemical Society) in Postępy Biochemii
- Vol. 70 (2) , 230-245
Open AccessRola i wykorzystanie badań wysokoprzepustowych w poszukiwaniu związków chemicznych o działaniu terapeutycznym
With the development of medicine and the aging population, the demand for more effective therapies is escalating. A tool that facilitates the discovery and introduction of new therapeutic drugs is High-Throughput Screening (HTS). These tests, consisting of a wide set of various assays, allow testing hundreds of thousands of compounds in a short period of time. The aim is to accurately identify active compounds that could become potential therapeutic candidates in the pharmaceutical industry. HTS is the first step in the quest for potential drugs, therefore it is one of the crucial tests that determine whether a particular drug candidate will be discovered. In this review, different stages of high-throughput screening studies will be described, as well as methods utilized in these studies. The necessary steps in the optimization of these tests, selection of equipment, automation and key quality control parameters for reliably performed screening will also be presented.
- Open Access
- 29 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (5) , 2818
Quantification of Circulating Cell-Free DNA in Idiopathic Parkinson’s Disease Patients
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders globally and leads to an excessive loss of dopaminergic neurons in the substantia nigra of the brain. Circulating cell-free DNA (ccf-DNA) are double-stranded DNA fragments of different sizes and origins that are released into the serum and cerebrospinal fluid (CSF) due to cell death (i.e., necrosis and apoptosis) or are actively released by viable cells via exocytosis and NETosis. Using droplet digital polymerase chain reaction (ddPCR), we comprehensively analyzed and distinguished circulating cell-free mitochondrial DNA (ccf mtDNA) and circulating cell-free nuclear DNA (ccfDNA) in the serum and CSF of PD and control patients. The quantitative analysis of serum ccf-DNA in PD patients demonstrated a significant increase in ccf mtDNA and ccfDNA compared to that in healthy control patients and a significantly higher copy of ccf mtDNA when compared to ccfDNA. Next, the serum ccf mtDNA levels significantly increased in male PD patients compared to those in healthy male controls. Furthermore, CSF ccf mtDNA in PD patients increased significantly compared to ccfDNA, and ccf mtDNA decreased in PD patients more than it did in healthy controls. These decreases were not statistically significant but were in agreement with previous data. Interestingly, ccf mtDNA increased in healthy control patients in both serum and CSF as compared to ccfDNA. The small sample size of serum and CSF were the main limitations of this study. To the best of our knowledge, this is the first comprehensive study on serum and CSF of PD patients using ddPCR to indicate the distribution of the copy number of ccf mtDNA as well as ccfDNA. If validated, we suggest that ccf mtDNA has greater potential than ccfDNA to lead the development of novel treatments for PD patients.
- 29 February 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (5) , 2818
Open AccessQuantification of Circulating Cell-Free DNA in Idiopathic Parkinson’s Disease Patients
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders globally and leads to an excessive loss of dopaminergic neurons in the substantia nigra of the brain. Circulating cell-free DNA (ccf-DNA) are double-stranded DNA fragments of different sizes and origins that are released into the serum and cerebrospinal fluid (CSF) due to cell death (i.e., necrosis and apoptosis) or are actively released by viable cells via exocytosis and NETosis. Using droplet digital polymerase chain reaction (ddPCR), we comprehensively analyzed and distinguished circulating cell-free mitochondrial DNA (ccf mtDNA) and circulating cell-free nuclear DNA (ccfDNA) in the serum and CSF of PD and control patients. The quantitative analysis of serum ccf-DNA in PD patients demonstrated a significant increase in ccf mtDNA and ccfDNA compared to that in healthy control patients and a significantly higher copy of ccf mtDNA when compared to ccfDNA. Next, the serum ccf mtDNA levels significantly increased in male PD patients compared to those in healthy male controls. Furthermore, CSF ccf mtDNA in PD patients increased significantly compared to ccfDNA, and ccf mtDNA decreased in PD patients more than it did in healthy controls. These decreases were not statistically significant but were in agreement with previous data. Interestingly, ccf mtDNA increased in healthy control patients in both serum and CSF as compared to ccfDNA. The small sample size of serum and CSF were the main limitations of this study. To the best of our knowledge, this is the first comprehensive study on serum and CSF of PD patients using ddPCR to indicate the distribution of the copy number of ccf mtDNA as well as ccfDNA. If validated, we suggest that ccf mtDNA has greater potential than ccfDNA to lead the development of novel treatments for PD patients.
- Open Access
- 29 January 2024
- Published by MDPI AG in Preprints.org
Quantification of Circulating Cell-Free DNA in Idiopathic Parkinson’s Disease Patients
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders globally, and leads to an excessive loss of dopaminergic neurons in the substantia nigra of the brain. Circulating cell-free DNA (ccf-DNA) are double-stranded DNA fragments of different sizes and origins that are released into the serum and cerebrospinal fluid (CSF) due to cell death (i.e., necrosis and apoptosis) or are actively released by viable cells via exocytosis and NETosis. Methods: Using droplet digital polymerase chain reaction (ddPCR) we comprehensively analyzed and distinguished ccfDNA and ccf mtDNA in the serum and CSF of PD and control patients. Results: The quantitative analysis of serum ccf-DNA in PD patients demonstrated significant increase of ccf mtDNA and ccfDNA compared to healthy control patients and significantly higher copy of ccf mtDNA when compared to ccfDNA. Next, the serum ccf mtDNA levels significantly increased in male PD patients compared to healthy male controls. Furthermore, CSF ccf mtDNA in PD patients increased significantly compared to ccfDNA, and ccf mtDNA decreased in PD patients compared to healthy controls. These decreases were not statistically significant, but were in agreement with previous data. In-terestingly, ccf mtDNA increased in healthy control patients in both serum and CSF as compared to ccfDNA. Limitations: the small sample size of serum and CSF were the main limitations of this study. Conclusion: To the best of our knowledge, this is the first comprehensive study on serum and CSF of PD patients using ddPCR and indicating the distribution of the copy number of ccf mtDNA, as well as ccfDNA. If validated, we suggest that ccf mtDNA has greater than ccfDNA potential to lead the development of novel treatments for PD patients.
- 29 January 2024
- Published by MDPI AG in Preprints.org
Open AccessQuantification of Circulating Cell-Free DNA in Idiopathic Parkinson’s Disease Patients
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders globally, and leads to an excessive loss of dopaminergic neurons in the substantia nigra of the brain. Circulating cell-free DNA (ccf-DNA) are double-stranded DNA fragments of different sizes and origins that are released into the serum and cerebrospinal fluid (CSF) due to cell death (i.e., necrosis and apoptosis) or are actively released by viable cells via exocytosis and NETosis. Methods: Using droplet digital polymerase chain reaction (ddPCR) we comprehensively analyzed and distinguished ccfDNA and ccf mtDNA in the serum and CSF of PD and control patients. Results: The quantitative analysis of serum ccf-DNA in PD patients demonstrated significant increase of ccf mtDNA and ccfDNA compared to healthy control patients and significantly higher copy of ccf mtDNA when compared to ccfDNA. Next, the serum ccf mtDNA levels significantly increased in male PD patients compared to healthy male controls. Furthermore, CSF ccf mtDNA in PD patients increased significantly compared to ccfDNA, and ccf mtDNA decreased in PD patients compared to healthy controls. These decreases were not statistically significant, but were in agreement with previous data. In-terestingly, ccf mtDNA increased in healthy control patients in both serum and CSF as compared to ccfDNA. Limitations: the small sample size of serum and CSF were the main limitations of this study. Conclusion: To the best of our knowledge, this is the first comprehensive study on serum and CSF of PD patients using ddPCR and indicating the distribution of the copy number of ccf mtDNA, as well as ccfDNA. If validated, we suggest that ccf mtDNA has greater than ccfDNA potential to lead the development of novel treatments for PD patients.